gadoteric acid (Dotarem) Report issue

Small molecule Imaging Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Gadoteric acid, sold under the brand name Dotarem among others, is a macrocycle-structured gadolinium-based MRI contrast agent (GBCA). It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd3+), and is used in form of the meglumine salt (gadoterate meglumine). The paramagnetic property of gadoteric acid reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in MRI, which is the source of its clinical utility. Because it has magnetic properties, gadoteric acid develops a magnetic moment when put under a magnetic field, which increases the signal intensity (brightness) of tissues during MRI imaging.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$9.3740 - $119.9933
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

[2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl-κ4n1,n4,n7,n10)tetraacetato(3−)]gadolinium | dota-gd | dotarem | gadolinate(1-), (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)- | gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate | gadolinium dota | gadoterate | gadoterate dimeglumine | gadoterate meglumine | gadoterate sodium | gadoteric acid | gd-dota | gd-dota meglumine | magnescope | meglumine gadoterate | p-449

Organizations (33)

Research & Development (32)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (31)

Approved Indications (1)


 

Diagnostic Imaging (approved 2013)

Experimental Indications - Clinical Trial Phases 1-4 (30)


 

Adenoma (Early Phase 1)

Anesthesia, Local (Phase 2)

Arterial Occlusive Diseases (Phase 4)

Arteries (Phase 4)

Autoimmune Diseases (Phase 1)

Brain Diseases (Phase 4)

Brain Neoplasms (Phase 4)

Breast Diseases (Phase 4)

Breast Neoplasms (Early Phase 1)

Carcinoma, Hepatocellular (Phase 4)

Central Nervous System Diseases (Phase 3)

Cerebral Arterial Diseases (Phase 3)

Cognition (Phase 4)

Contrast Media (Phase 4)

Diagnostic Self Evaluation (Phase 3)

Hip Fractures (Phase 2)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 1)

Lung Diseases, Interstitial (Phase 2)

Magnetic Resonance Imaging (Phase 4)

Meniere Disease (Phase 4)

Motor Activity (Phase 4)

Neoplasms (Phase 4)

Nephrogenic Fibrosing Dermopathy (Phase 4)

Pain (Phase 1)

Pain, Postoperative (Phase 2)

Peripheral Arterial Disease (Phase 4)

Renal Artery Obstruction (Phase 3)

Renal Insufficiency (Phase 4)

Renal Insufficiency, Chronic (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 34
  • # of Trial Organizations: 32

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue